[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515739":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":10,"centralContacts":10,"locations":30,"responsibleParty":50,"collaborators":10,"id":52,"slug":10,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":10,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":33,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Xuanwu Hospital, Beijing","OTHER",[8,14,18,22],{"label":9,"type":10,"description":11,"interventionNames":12},"amnestic mild cognitive impairment(aMCI）",null,"1. aMCI diagnostic criteria of National Institute of Aging and National Association of Alzheimer's Disease (NIA-AA).\n2. The ClinicalDementiaRating scale (CDR) is 0.5.\n3. Mini-MentalStateExamination (MMSE): MMSE≥17 for those with 0 years of education, ≥20 for those with less than 7 years, and ≥24 for those with more than 7 years.\n4. Memory impairment is prominent, and it may also be accompanied by functional impairment of other cognitive domains.\n5. The onset is insidious and the progress is slow.\n6. Not up to the level of dementia",[13],"Other: There was no intervention as this was an observational study.",{"label":15,"type":10,"description":16,"interventionNames":17},"mild AD","Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the mild AD group with a CDR score of 1.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"severe AD","Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the severe AD group with a score of 3.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Moderate AD","Clinical dementia rating (CDR) was used to assess and determine the degree of cognitive impairment of the patients, according to the CDR score, where the moderate group with a score of 2.",[13],[27],{"type":6,"name":28,"description":28,"armGroupLabels":29,"otherNames":10},"There was no intervention as this was an observational study.",[23,9,15,19],[31],{"facility":32,"status":33,"city":34,"state":10,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Xuanwu Hospital, Capital Medical University","RECRUITING","Beijing","100053","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":46,"role":47,"phone":48,"phoneExt":10,"email":49},"Yi Tang, M.D., Ph.D.","CONTACT","00861083199456","tangyixw@vip.163.com",{"type":51,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100515739",false,"NCT05995418","Study on the Health Economic Burden of Alzheimer's Disease in China","The Alzheimer's Disease Burden in China (ABC) Study: a Nationwide Multicentre Cross-sectional and Prospective Cohort Study","Diagnosed according to the National Institute on Aging-Alzheimer's 1.Association (NIA-AA) criteria for aMCI and AD.\n\n2.Clinical Dementia Rating (CDR) score greater than or equal to 0.5 3.Have good visual, auditory, and language functions, or can complete neuropsychological assessments after correction.\n\n4.Participants or their legal representatives sign informed consent. Exclusion criteria\n\n1. History of stroke with neurological focal signs and imaging findings consistent with cerebral small vessel disease (Modified Fazekas score ≥2).\n2. Presence of mental or neurological developmental delay.\n3. Presence of other known conditions that may cause cognitive impairment.\n4. Diagnosis of a disease that prevents completion of cognitive assessments.\n5. Refusal to sign informed consent at baseline.","ALL","40 Years","100 Years",{"count":62,"type":63},9510,"ESTIMATED","OBSERVATIONAL","Alzheimer's disease (AD) presents a significant socio-economic challenge globally, with China experiencing a notable rise in its prevalence. This study addresses critical gaps in understanding AD's economic burden and quality of life (QoL) impacts on patients and caregivers in Mainland China.",[67],"Alzheimer Disease","2026-06-04",{"date":70,"type":71},"2026-06-05","ACTUAL",{"date":73,"type":71},"2023-07-01",{"date":75,"type":63},"2027-01-01",{"name":5,"class":6},1]